Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks. RESEARCH DESIGN AND METHODS: In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine. RESULTS: The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE HbA1c change from baseline to the primary end point was −1.08 ± 0.06% (−11.8 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −0.76 ± 0.06% (−8.3 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, and −0.63 ± 0.06% (−6.9 ± 0.7 mmol/mol) for glargine, with an end point mean ± SD dose of 29 ± 26 units (0.33 ± 0.24 units/kg), and a fasting plasma glucose (mean ± SD) of 118 ± 23 mg/dL from self-monitored plasma glucose. Statistical criteria for superiority were met with dulaglutide 1.5 mg and for noninferiority with dulaglutide 0.75 mg. More patients on dulaglutide 1.5 mg achieved HbA1c targets <7.0% (53 mmol/mol) versus glargine (P < 0.001). Body weight decreased with dulaglutide and increased with glargine. Total hypoglycemia rates were lower with dulaglutide; severe hypoglycemia was minimal. Increases in pancreatic enzymes were observed for dulaglutide. Incidence of nausea (15.4, 7.7, and 1.5%) and diarrhea (10.6, 9.2, and 5.7%) were more common with dulaglutide 1.5 mg and 0.75 mg than with glargine. CONCLUSIONS: Once-weekly dulaglutide 1.5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“In trials analyzing the addition of an injectable GLP-1 RA, dual GIP and GLP-1 RA, or insulin in people needing further glucose lowering, glycemic efficacies of GLP-1 RAs and the dual GIP and GLP-1 RA were similar to or greater than that of basal insulin (123-130).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [127]
In the citing paper
“It is worth mentioning that in the AWARD-2 study, there were several cases of pancreatitis caused by DUL (112).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [112]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699 · cited 11×
“%) at least once after baseline; dulaglutide-neutralizing antibodies developed in 5, but no native sequence GLP-1neutralizing–antibodies developed.”
BackgroundInfluentialRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Thomas, G. E., Westfall, P. H., & Young, S. S. (1994) · The Statistician · doi:10.2307/2348369 · Cited by 513
Cited by
Items 201–269 of 269
Lee, J., Kim, H. S., Jung, C. H., Park, J., & Lee, W. J. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3466 · Cited by 4
Ayesh, H., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100284 · Cited by 5
Singh, A. K., & Singh, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1318061 · Cited by 4
“on agents to metformin plus SUs and metformin plus pioglitazone [38,39,44,45].”
BackgroundTerui, S., Akamatsu, R., Arai, M., Inoue, R., Okuyama, T., Kyohara, M., Li, J., Tsuno, T., Miyashita, D., Togashi, Y., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01147-2 · Cited by 3
Kheniser, K. G., Aminian, A., & Kashyap, S. R. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0039 · Cited by 4
Incretin-based therapies and cancer risk: a review of recent literature safety data
Scavone, C., Sportiello, L., Rafaniello, C., Fiorentino, S., Cimmaruta, D., Rossi, F., & Capuano, A. (2016) · Diabetes Management · Cited by 5
Romera, I., Conget, I., Vázquez, L. A., Gentilella, R., Lebrec, J., Jódar, E., & Reviriego, J. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107575 · Cited by 3
Xu, L., Yu, S. Q., Gao, L., Huang, Y., Wu, S., Yang, J., Sun, Y. X., Yang, Z., Chai, S. B., Zhang, Y., et al. (2020) · PubMed · doi:10.3967/bes2020.005 · Cited by 3
Hoog, M. M., Paczkowski, R., Huang, A., Halpern, R., Buysman, E. K., Stackland, S., Zhang, Y., & Dixon, R. W. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01473-7 · Cited by 2
“0% (53 mmol/mol), compared with treatment with basal insulin [17].”
BackgroundKim, M. J., Kim, H. S., Cho, Y. K., Jung, C. H., & Lee, W. J. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.06.024 · Cited by 2
Glucagon-like peptide-1 agonists for weight loss in people with obesity
Kirk, S., Shamliyan, T., & Middleton, M. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.01.003 · Cited by 2
Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
Lee, I., & Kang, E. S. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.3.149 · Cited by 2
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists
Gillenwater, B. A., Wakefield, A. N., Triboletti, J. S., Gonzalvo, J. D., & Meredith, A. H. (2019) · AADE in Practice · doi:10.1177/2325160319861453 · Cited by 2
Bossi, A. C., Mori, V. D., Scaranna, C., Veronesi, G., Lepore, G., the ANDREW study group, Barbara, A., Rosalia, B., Antonio, B., Berzi, D., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00929-4 · Cited by 2
Houssarini, J. A., Brnabic, A. J. M., & Obaid, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01184-x · Cited by 1
“Assumptions for the HbA1c were based on the AWARD2 trial [14].”
MethodResultBai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 2
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Violante-Ortiz, R. M., Rose, L., Sharma, P., Valderas, E. G., Chivukula, K. K., & Kwan, A. Y. M. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005711 · Cited by 1
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Zhou, L., Wu, P., Xu, Y., & Xie, B. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02697-2 · Cited by 2
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Chen, T., Tseng, C.-J., Li, Y., Lin, Y., Chen, D., Yang, N., Wang, T.-H., Hung, M., & Tsai, M. (2025) · Acta Diabetologica · doi:10.1007/s00592-024-02443-6 · Cited by 1
“Moreover, hypoglycemia risk was lower not only in the current study but also in other trials comparing insulin and GLP-1 RAs [ 16 , 17 ].”
Tamaki, C., Takeuchi, M., Iwamoto, N., & Glaesner, W. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.146.215 · Cited by 1
Dulaglutide – New in the Treatment of Type 2 Diabetes
Yegshatyan, L. V., Khachaturian, N., & Mkrtumyan, A. M. (2019) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2019-15-25-20-28 · Cited by 1
Dulaglutide‑pharmacological profile
Adamíková, A. (2019) · Interní medicína pro praxi · doi:10.36290/int.2019.011 · Cited by 1
Consoli, A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_21 · Cited by 1
Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes
Clements, J. N., Moore, K. G., & Shealy, K. M. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1098532
Real-World-Wirkungen von Dulaglutide bei Patienten, betreut in Diabetologischen Schwerpunktpraxen
Göke, R., Marck, C., Zerth, G., Ingo, N., & KLEPZIG, C. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-124422
“[9] Giorgino F, Benroubi M, Sun JH et al.”
BackgroundOrale Triple-Therapie – sinnvolle Strategie oder nur Verzögerungstaktik?
Ritzel, R. A. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0253-3
Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
Pogorelova, A. S., & Fadeev, V. V. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-4-36-41
Efficacy of dulaglutide: an evidence-based review of its potential indications
Biryukova, E. V., & Solovyeva, I. V. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-18-30
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_44
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-2
Treating Type 2 Diabetes Mellitus
Migdal, A. L., & Abrahamson, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-1
Consoli, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_21-1
Zyryanov, S. K., & Dyakov, I. N. (2022) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2021-4-15
(2018) · doi:10.31038/edmj.2018244
“06 achieved, was a wee bit less than that achieved in our subjects; who, however had a mean duration of follow up of just over 41 weeks [13].”
BackgroundHert, S. G. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734529586.793559018
Effect of dulaglutide injection on weight beyond glycemic control: real-world observational study
Mohammed, A. G., & Odhaib, S. A. (2023) · Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale · doi:10.4081/jbr.2023.10643
Therapy Simplification with Dulaglutide in Elderly Patients: A Real World Study
Occhipinti, M., Baccetti, F., Bertoli, S., Cosimi, S., Casadidio, I., Cuccuro, I., Carlo, A. D., Gregori, G., Mori, M., Lacaria, E., et al. (2023) · Journal of Diabetes Research Review & Reports · doi:10.47363/jdrr/2023(5)168
Shi, L., Meng, S., & Ruan, Y. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.4.13
Choice of Therapy in Obese Type 2 Diabetes
Jyotsna, V., & Deshmukh, S. (2022) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_2_22
Morioka, T., Takeuchi, M., Ozeki, A., & Emoto, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15644
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Carson, E., Khaleq, F., McDonald, C., Smith, N., & Colon, A. R. (2025) · Cureus · doi:10.7759/cureus.88898 · Cited by 1
“After dose optimization, the average HbA1c reduction in this cohort was -0.84% (P = 0.008), which is similar to reductions in the AWARD-2 and AWARD-3 trials for dulaglutide 1.5 mg (-1.08% and -0.78%, respectively) [8,9].”
InfluentialXu, Y., Ji, G., Shi, C., Tan, Y., Wang, L., & Gui, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112954
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Ugamura, D., Hosojima, M., Kabasawa, H., Tanabe, N., Yoshizawa, Y., Suzuki, Y., Saito, A., & Narita, I. (2022) · Figshare · doi:10.6084/m9.figshare.20056574
Ugamura, D., Hosojima, M., Kabasawa, H., Tanabe, N., Yoshizawa, Y., Suzuki, Y., Saito, A., & Narita, I. (2022) · Figshare · doi:10.6084/m9.figshare.20056571
Ugamura, D., Hosojima, M., Kabasawa, H., Tanabe, N., Yoshizawa, Y., Suzuki, Y., Saito, A., & Narita, I. (2022) · Figshare · doi:10.6084/m9.figshare.20056559
Ugamura, D., Hosojima, M., Kabasawa, H., Tanabe, N., Yoshizawa, Y., Suzuki, Y., Saito, A., & Narita, I. (2022) · Figshare · doi:10.6084/m9.figshare.20056562
Ugamura, D., Hosojima, M., Kabasawa, H., Tanabe, N., Yoshizawa, Y., Suzuki, Y., Saito, A., & Narita, I. (2022) · Figshare · doi:10.6084/m9.figshare.20056577
Ugamura, D., Hosojima, M., Kabasawa, H., Tanabe, N., Yoshizawa, Y., Suzuki, Y., Saito, A., & Narita, I. (2022) · Figshare · doi:10.6084/m9.figshare.20056568
Khawandanah, D. O., Alyamani, F. F., Almutairi, B. R., Almutairi, B. A., Alharbi, R. M., Alghanmi, S., Alsouri, M. T., & ALMUTAIRI, A. R. (2025) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_22_25 · Cited by 1
Eisa, N., & Barood, O. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.003 · Cited by 1
Gomes, K. D. S., de Souza, P. P., Pieretti, N. P. L., Almeida, E. A., Bernardo, R., Filho, W. Q. M., Fedatto, P. F., & Gomez, A. P. B. (2026) · Scripta Scientia · doi:10.66201/ss.v1.10
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Chae, H. H., Luo, C., Harriman, D. I., & Nguan, C. (2026) · Canadian Urological Association Journal · doi:10.5489/cuaj.9689
Lenham, R. K., Elgammal, F., Harding, S., & Berry, M. D. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_821
Stewart, K. D., Matza, L. S., Chinthammit, C., Pavo, I. J., Bartee, A. K., & Boye, K. S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01907-y
(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease
Bovee, L. B., & Thirumalai, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00469-y
Floyd, K., Sharma, M., & Du, X. (2026) · Food Research International · doi:10.1016/j.foodres.2026.121169
Metadata
- Authors
- Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V.
- Affiliations
- University of Bari Aldo Moro (IT)
- Evangelismos-Polyclinic, Athens General Hospital, Athens, Greece
- Chang Gung Memorial Hospital (TW)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Neuilly-Sur-Seine Cedex, France
- Corresponding author
- Pechtner, Valeria
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-06-18
- Volume
- 38
- Issue
- 12
- Pages
- 2241-2249
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W906438903
- Cited by
- 268
- References
- 27
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 17 · 2023: 20 · 2022: 19 · 2021: 21 · 2020: 22 · 2019: 28 · 2018: 29 · 2017: 27 · 2016: 23 · 2015: 17
- FWCI
- 27.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dulaglutide, insulin glargine, type 2 diabetes, GLP-1 receptor agonists, metformin, glimepiride, HbA1c, glycemic control, non-inferiority, hypoglycemia, body weight, pancreatic enzymes, nausea, drug safety, dose comparison
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Recombinant Fusion Proteins, Sulfonylurea Compounds, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.